# NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer

> **NCT00749346** · PHASE1,PHASE2 · COMPLETED · sponsor: **NovoCure Ltd.** · enrollment: 42 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- NSCLC

## Interventions

- **DEVICE:** NovoTTF-100L

## Key facts

- **NCT ID:** NCT00749346
- **Lead sponsor:** NovoCure Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2011-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00749346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00749346, "NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00749346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*